论文部分内容阅读
急性缺血性脑卒中是一种高发病率、高死亡率、高致残率疾病,目前国际公认的最有效的治疗方法为静脉溶栓治疗,指南特别推荐重组组织型纤溶酶原激活剂(rt-PA)作为首选溶栓药物。1995年由美国国立神经病与中风研究所主持的一个具有里程碑意义的临床试验——重组组织型纤溶酶原激活剂治疗脑卒中试验,结果提示急性缺血性脑卒中病人起病3h内用rtPA治疗,在3个月时至少30%的病人没有残疾或仅
Acute ischemic stroke is a high incidence, high mortality, high morbidity diseases, the most internationally accepted current treatment of intravenous thrombolytic therapy, the guidelines specifically recommended recombinant tissue-type plasminogen activator (rt-PA) as the preferred thrombolytic drug. A landmark clinical trial conducted in 1995 by the National Institute of Neurological Disorders and Stroke - recombinant tissue plasminogen activator in the treatment of stroke trials showed that patients with acute ischemic stroke were treated with rtPA within 3 h of onset Treatment, at 3 months, at least 30% of patients have no disability or only